期刊文献+

老年进展期非小细胞肺癌药物治疗的选择及问题 被引量:7

下载PDF
导出
摘要 2008年全球肺癌新发病例大约为160万,死亡138万,居恶性肿瘤首位,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占全部肺癌的80%~85%。2004~2006年美国〈39岁居民中肺癌年龄调整发病率为0.03%,而≥70岁的年龄调整发病率达5.56%。
出处 《疑难病杂志》 CAS 2012年第1期66-69,共4页 Chinese Journal of Difficult and Complicated Cases
基金 首都医学发展科研基金(中医药类)(No.SF-2007-I-07)
  • 相关文献

参考文献40

  • 1Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(1):1-22. 被引量:1
  • 2Jemal A,Siegel R,Xu JQ,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300. 被引量:1
  • 3储大同主编..老年肿瘤学[M].北京:人民卫生出版社,2009:199.
  • 4Takanori K,Masaki H,Hideki T,et al.Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan[J].J Med Invest,2010,57(8):326-333. 被引量:1
  • 5Gridelli C.The ELVIS trail:A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer,elderly lung cancer vinorelbine Italian study[J].Oncologist,2001,6(suppl 1):4. 被引量:1
  • 6José MTP,Pilar GL,Enriqueta FF,et al.SEOM clinical guidelines for the treatment of non-small-cell lung cancer:an updated edition[J].Clin Transl Oncol,2010,12(9):735-741. 被引量:1
  • 7Veronesi A,Crivellari D,Magri MD,et al.Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients[J].Eur J Cancer,1996,32A(10):1809-1811. 被引量:1
  • 8Gridelli C,Perrone F,Gallo C,et al.Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer:a two-stage Phase II study[J].Eur J Cancer,1997,33(3):392-397. 被引量:1
  • 9Buccheri G,Ferrigno D.Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma:phase II study[J].Cancer,2000,88(12):2677-2685. 被引量:1
  • 10Gridelli C,Perrone F,Gallo C,et al.Chemotherapy for elderly patients with advanced non-small-cell lung cancer:The multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial[J].J Natl Cancer Inst,2003,95(5):362-372. 被引量:1

二级参考文献40

共引文献36

同被引文献84

  • 1孙燕,周际昌.临床肿瘤内科手册[M].4版.北京:人民卫生出版社.2002:69-70. 被引量:2
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ] CACancerJClin, 2011, 61 (2): 69-90. 被引量:1
  • 3Chen Z, Luo Q, Jian H, et al. Long - term results of a randomized controlled trial evaluating preoperative chemotherapy in resectable non -small cell lung cancer [J]. Oncotargets Ther, 2013, 6:645 -650. 被引量:1
  • 4Eroglu C, Orhan O, Unal D, et al. Concomitant chemoradiotherapy with doeetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non -small cell lung cancer [ J ]. Ann Thorac Med, 2013, 8 (2): 109-115. 被引量:1
  • 5Salama JK, Vokes EE. New radiotherapy and ehemoradiotherapy approaches for non - small - cell lung cancer [ J ]. J Clin Oneol, 2013, 31 (8): 1029-1038. 被引量:1
  • 6Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic Adenocarcinoma, Version 2.2012: featured updates to the NCCN guidelines [J], J Natl Compr 'Canc Netw, 2012, 10 (6): 703 -713. 被引量:1
  • 7Herbst RS, Khuri FR. Mode of action of docetaxel a basis for combination with novel anticancer agents [ J]. Cancer Treat Rev, ; 003, 29 (5): 407-415. 被引量:1
  • 8Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel : a review [ J ]. Antieancer Drugs, 2007, 18 (2) : 95 - 103. 被引量:1
  • 9Chen Z,Cheng K,Walton Z,et al.A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response[J].Nature,2012,483(7391):613-617. 被引量:1
  • 10Fukuoka M,Wu YL,Thongprasert S,et al.Biomarker analyses and final overall survival results from a phase HI,randomized,open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia(IPASS)[J].J Clin Oncol,2011,29(21):2866-2874. 被引量:1

引证文献7

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部